155 related articles for article (PubMed ID: 4033706)
1. The effect of dietary protein on the clearance of allopurinol and oxypurinol.
Berlinger WG; Park GD; Spector R
N Engl J Med; 1985 Sep; 313(13):771-6. PubMed ID: 4033706
[TBL] [Abstract][Full Text] [Related]
2. Difference of the plasma concentration and urinary excretion of allopurinol, oxypurinol, and purine bases between dietary intake and fasting.
Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Yamakita J; Higashino K
Int J Clin Pharmacol Ther; 1996 Apr; 34(4):157-62. PubMed ID: 8861734
[TBL] [Abstract][Full Text] [Related]
3. Sustained reductions in oxipurinol renal clearance during a restricted diet.
Park GD; Berlinger WG; Spector R; Kitt TM; Tsalikian E
Clin Pharmacol Ther; 1987 Jun; 41(6):616-21. PubMed ID: 3581647
[TBL] [Abstract][Full Text] [Related]
4. Influence of two diets on pharmacokinetic parameters of allopurinol and oxypurinol in healthy beagles.
Bartges JW; Osborne CA; Felice LJ; Koehler LA; Ulrich LK; Bird KA; Chen M
Am J Vet Res; 1997 May; 58(5):511-5. PubMed ID: 9140560
[TBL] [Abstract][Full Text] [Related]
5. Effect of furosemide on renal excretion of oxypurinol and purine bases.
Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Hada T
Metabolism; 2001 Feb; 50(2):241-5. PubMed ID: 11229436
[TBL] [Abstract][Full Text] [Related]
6. Effect of losartan potassium, an angiotensin II receptor antagonist, on renal excretion of oxypurinol and purine bases.
Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Hada T
J Rheumatol; 2000 Sep; 27(9):2232-6. PubMed ID: 10990239
[TBL] [Abstract][Full Text] [Related]
7. Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol.
Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Hada T
J Rheumatol; 2001 Oct; 28(10):2294-7. PubMed ID: 11669172
[TBL] [Abstract][Full Text] [Related]
8. Reduced renal clearance of oxypurinol during a 400 calorie protein-free diet.
Kitt TM; Park GD; Spector R; Tsalikian E
J Clin Pharmacol; 1989 Jan; 29(1):65-71. PubMed ID: 2708550
[TBL] [Abstract][Full Text] [Related]
9. [Clinical pharmacokinetics of allopurinol. 3. Allopurinol/oxipurinol pharmacokinetics following administration of a controlled release allopurinol preparation].
Gikalov I; Radivojevich F; Schiemann O; Fenner H
Arzneimittelforschung; 1986 Jun; 36(6):988-93. PubMed ID: 3741536
[TBL] [Abstract][Full Text] [Related]
10. Placental transfer and pharmacokinetics of allopurinol in late pregnant sows and their fetuses.
van Dijk AJ; Parvizi N; Taverne MA; Fink-Gremmels J
J Vet Pharmacol Ther; 2008 Dec; 31(6):489-95. PubMed ID: 19000269
[TBL] [Abstract][Full Text] [Related]
11. [The clinical pharmacokinetics of allopurinol. 2. Allopurinol/oxypurinol pharmacokinetics following allopurinol in single doses and multiple application].
Fenner H; Schiemann O; Gikalov I
Arzneimittelforschung; 1985; 35(7):1093-6. PubMed ID: 4052144
[TBL] [Abstract][Full Text] [Related]
12. [Influence of benzbromarone on the pharmacokinetics and pharmacodynamics of oxipurinol].
Rüffer C; Zorn G; Henkel E; Mitzkat HJ
Arzneimittelforschung; 1982; 32(9):1149-52. PubMed ID: 6890841
[TBL] [Abstract][Full Text] [Related]
13. [Excretion and serum concentrations of allopurinol, oxipurinol and oxipurines in combined treatment with allopurinol and benzbromarone in increasing doses].
Mertz DP; Borner K
Med Welt; 1983 Sep; 34(36):974-9. PubMed ID: 6633222
[No Abstract] [Full Text] [Related]
14. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.
Day RO; Graham GG; Hicks M; McLachlan AJ; Stocker SL; Williams KM
Clin Pharmacokinet; 2007; 46(8):623-44. PubMed ID: 17655371
[TBL] [Abstract][Full Text] [Related]
15. [The clinical pharmacokinetics of allopurinol. 1. Allopurinol absorption sites and dose proportionality of allopurinol/oxipurinol bioavailability].
Schuster O; Haertel M; Hugemann B; Gikalov I; Schiemann O; Fenner H
Arzneimittelforschung; 1985; 35(4):760-5. PubMed ID: 4015743
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetic studies on plasma elimination half-life of oxipurinol (author's transl)].
Lach HJ; Bader B; Schnitker J; Harries EH
Arzneimittelforschung; 1982; 32(1):76-9. PubMed ID: 7199345
[TBL] [Abstract][Full Text] [Related]
17. Plasma concentrations and urinary excretion of purine bases (uric acid, hypoxanthine, and xanthine) and oxypurinol after rigorous exercise.
Kaya M; Moriwaki Y; Ka T; Inokuchi T; Yamamoto A; Takahashi S; Tsutsumi Z; Tsuzita J; Oku Y; Yamamoto T
Metabolism; 2006 Jan; 55(1):103-7. PubMed ID: 16324927
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability and pharmacokinetics of intravenously and orally administered allopurinol in healthy beagles.
Bartges JW; Osborne CA; Felice LJ; Koehler LA; Ulrich LK; Bird KA; Chen M; Sawchuk RJ
Am J Vet Res; 1997 May; 58(5):504-10. PubMed ID: 9140559
[TBL] [Abstract][Full Text] [Related]
19. Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.
Colin JN; Farinotti R; Fredj G; Tod M; Clavel JP; Vignon E; Dietlin F
Eur J Clin Pharmacol; 1986; 31(1):53-8. PubMed ID: 3780828
[TBL] [Abstract][Full Text] [Related]
20. Effect of glucagon on renal excretion of oxypurinol and purine bases.
Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Hiroishi K; Yamakita J; Nakano T; Higashino K
J Rheumatol; 1997 Apr; 24(4):708-13. PubMed ID: 9101506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
